April 27, 2018 / 7:52 PM / 3 months ago

BRIEF-Teva Presents New Long-Term Data Demonstrating Efficacy & Safety Of Copaxone 40 Mg/Ml

April 28 (Reuters) - Teva Pharmaceutical Industries Ltd :

* TEVA PRESENTS NEW LONG-TERM DATA DEMONSTRATING EFFICACY AND SAFETY OF COPAXONE (GLATIRAMER ACETATE INJECTION) 40 MG/ML

* TEVA PHARMACEUTICAL INDUSTRIES LTD - NO NEW OR UNEXPECTED ADVERSE EVENTS EMERGED IN PATIENTS RECEIVING COPAXONE 40 MG/ML FOR UP TO 7 YEARS

* TEVA PHARMACEUTICAL INDUSTRIES LTD - ADVERSE EVENTS WERE GENERALLY MILD AND CONSISTENT WITH WELL-ESTABLISHED SAFETY PROFILE OF COPAXONE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below